Rivaroxaban Evaluation in Real Life Settings "RIVER"


Phase N/A Results N/A

Eligibility Criteria

Inclusion Criteria

- Written informed consent
- Age 18 years and over
- New diagnosis of non-valvular atrial fibrillation (diagnosed within the last 6 weeks) with at least one additional investigator-determined risk factor for stroke and regardless of therapy

Exclusion Criteria

- No further follow-up envisaged or possible within enrolling hospital or with associated family practitioner.
- Patients with transient AF secondary to a reversible cause.
- According to the European Directive 2001/20/EC, patients recruited in controlled clinical trials are not eligible for registries